Moderna (MRNA) to Release Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) will likely be posting its quarterly earnings results before the market opens on Friday, February 14th. Analysts expect Moderna to post earnings of ($2.86) per share and revenue of $951.09 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Moderna Stock Down 2.9 %

Shares of MRNA stock opened at $30.93 on Wednesday. Moderna has a fifty-two week low of $30.70 and a fifty-two week high of $170.47. The firm has a market capitalization of $11.90 billion, a PE ratio of -5.31 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock’s 50-day simple moving average is $39.77 and its 200-day simple moving average is $56.76.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Berenberg Bank lifted their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective for the company. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $66.89.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last ninety days. Corporate insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.